Splanchnic Vein Thrombosis Clinical Trial
Official title:
Evaluation of Safety and Efficacy of Anticoagulation Treatment in Patients With Splanchnic Vein Thrombosis: SAPIENT Study
Prospective single-centre, observational study with medical products. Patients with a medical history of SVT will be observed for at least 24 months after inclusion. The study will begin when the patient is referred to our centre for SVT and will end at the 24-month follow-up or at the occurrence of a study outcome event, or in case of Death OBJECTIVE: To prospectively define the incidence of recurrent thrombosis and bleeding events during anticoagulant therapy in patients with diagnosed SVT, regardless of whether they will be hospitalized or treated as outpatients
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT04994158 -
MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
|
||
| Recruiting |
NCT03778502 -
DOAC in Unusual Site Venous Thrombosis
|
||
| Active, not recruiting |
NCT04631458 -
Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
|
||
| Active, not recruiting |
NCT03080883 -
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
|
Phase 3 |